Switch to Dolutegravir Regimen Improves Lipid Profile in HIV+ Patients
Investigators performed a randomized, noninferiority, 96-week, strategic trial of dolutegravir to compare efficacy and effect on lipid parameters.
Since the first clinical observation of HIV/AIDS in 1981, some 35.4 million people have died from AIDS-related illnesses.
Investigators evaluated the safety and effectiveness of conventional therapy with biologic immunosuppressive drugs to treat patients with HIV infection and psoriasis.
Increased proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in people with HIV may be related to abnormal coronary endothelial function.